Showing 101 - 120 results of 122 for search '"hepatology"', query time: 0.09s Refine Results
  1. 101
  2. 102

    Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement) by M. V. Maevskaya, M. Yu. Nadinskaia, E. N. Bessonova, N. I. Geyvandova, M. S. Zharkova, E. A. Kitsenko, N. V. Korochanskaya, I. A. Kurkina, A. L. Melikyan, V. G. Morozov, Yu. V. Khoronko, T. A. Deeva, K. A. Gulyaeva, V. T. Ivashkin

    Published 2024-08-01
    “…The Russian Scientific Liver Society selected a panel of experts in the field of therapeutic and surgical hepatology, hematology, transfusion medicine to make reasoned statements and recommendations on the issue of treatment of thrombocytopenia before elective surgery / invasive procedures in patients with liver cirrhosis.Results. …”
    Get full text
    Article
  3. 103
  4. 104

    Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States by Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO

    Published 2025-02-01
    “…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email [email protected]: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
    Get full text
    Article
  5. 105
  6. 106

    Ginsenoside Rg1: A bioactive therapeutic agent for diverse liver diseases by Mingyu Wu, Ke Li, Jiabin Wu, Xianyi Ding, Xiaotong Ma, Wenhong Wang, Weihua Xiao

    Published 2025-02-01
    “…To delay the transition from benign tissue lesions to a substantial organ injury, scientists have gradually applied natural compounds derived from plants as a complementary therapy in the field of hepatology. Ginseng (Panax ginseng C. A. Meyer) is a tonic traditional Chinese herbal medicine, and natural products, including ginsenoside Rg1 (G-Rg1), which is a kind of 20(S)-protopanaxatriol saponin with a relatively high biological activity, can be isolated from the roots or stems of ginseng. …”
    Get full text
    Article
  7. 107
  8. 108
  9. 109
  10. 110

    Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres) by M. V. Mayevskaya, M. S. Novruzbekov, I. M. Borovkov, D. G. Trofimova, M. S. Zharkova, V. D. Lunkov, K. N. Lutsyk, O. D. Olisov

    Published 2020-05-01
    “…A retrospective analysis of the medical records of hepatological patients who sought medical treatment at to the V.Kh. …”
    Get full text
    Article
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116
  17. 117
  18. 118

    Liver Damage in Type 1 Diabetes Mellitus by A. O. Bueverov, A. V. Zilov

    Published 2021-06-01
    “…An up-to-date review of the prevalence, pathogenesis, diagnosis and management of hepatological complications of type 1 diabetes mellitus (T1D).Key points. …”
    Get full text
    Article
  19. 119

    Pegilated interferon α2а in treatment of chronic hepatitis C by P. O. Bogomolov, S. V. Koblov, A. O. Buyeverov, M. V. Matsiyevich, O. S. Kuzmina, N. A. Barsukova, N. V. Dubinina

    Published 2012-09-01
    “…Follow-up of CHC patients, treated by pegIFN-α2а and ribavirin in the Moscow regional hepatological center, testifies its high efficacy and safety profile.…”
    Get full text
    Article
  20. 120

    Urinary tract infections in patients with decompensated liver cirrhosis, listed for liver transplantation by P. D. Bessonov, I. V. Borzunov, E. N. Bessonova

    Published 2018-08-01
    “…The study included patients with liver cirrhosis Child Pugh class B and C with indications for liver transplantation, who were hospitalized at Sverdlovsk Regional hepatological center for liver disease decompensation in 2015 (n=137). …”
    Get full text
    Article